Latest Posts

BRENTWOOD, Tenn. (March 17, 2014)– PathGroup, one of the largest private providers of pathology services in the United States, today announced launch of the SmartGenomics™ Heme Profile, which provides genomic profiling and information for patients that have failed or been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas and myeloproliferative/myelodysplastic diseases.  The newly launched offering is based on collaboration between PathGroup, GenoSpace and the IP & Science business of Thomson Reuters.

The SmartGenomics™ Heme Profile includes Next-Generation DNA Sequencing (NGS) of 77 clinically actionable genes mutated in hematolymphoid cancers and is complemented by Array-based Comparative Genomic Hybridization (aCGH) for whole genome level identification of chromosomal copy number changes and loss of heterozygosity (LOH).  Results provide the treating oncologist with prognostic, predictive, and therapeutic information, as well as available clinical trial options.

Prevalence estimates from the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Cancer Statistics Review¹, indicate that there are approximately one million individuals in the country that are living with a diagnosis of Hodgkin disease, leukemia, multiple myeloma, or Non-Hodgkin lymphoma, in addition to myeloproliferative/myelodysplastic diseases.  Up to 50% of these diseases ultimately are refractory to treatment.  Furthermore, many of these malignancies are increasing in incidence and pose a significant health care burden.

“When PathGroup committed to providing genomic profiling to community oncologists and researchers, we understood early in the development process that independent interrogation of cancers originating in the bone marrow, blood, and lymphatic system, would be an imperative complement to any exploration of solid tumors,” stated Ben Davis, MD, Chairman, President and CEO of PathGroup.  “As was the case when we released SmartGenomics for solid tumors, we will continue to rely on the exceptional data aggregation and reporting that GenoSpace and Thomson Reuters afford PathGroup in modeling a best-in-class precision oncology offering.”

“The GenoSpace team has been honored to work with PathGroup and is impressed with their approach to developing an integrated personalized medicine offering,” said John Quackenbush, PhD, CEO of GenoSpace. “We are pleased to see PathGroup expand its use of the GenoSpace FullView™ platform to integrate and interpret complex genomic, clinical and demographic information to benefit patients with hematologic malignancies.”

Further, Joseph Donahue, senior vice president, Thomson Reuters Life Sciences commented, “Thomson Reuters is committed to collaborating with innovative organizations like PathGroup and GenoSpace to deliver valuable, new solutions for Life Science clinicians.  The latest phase of our work with these partners, in providing patient-specific genomic intelligence for stratifying cancers, is rooted in the high quality, curated content in Cortellis™, and brings us closer to finding more precise treatments and therapies for oncology patients, regardless of their tumor type or disease.”

¹ Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships.  PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com.

About GenoSpace

 At GenoSpace, we are Digital Architects of Genomic Medicine™. GenoSpace is a Cambridge, Massachusetts-based company that has developed robust software systems for securely storing vast amounts of genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical Care facilitates clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research provides dynamic analysis, visualization and collaboration tools. GenoSpace for Patient Communities enables patient-centric exploration and advancement of personalized medicine. Please visit www.GenoSpace.com for more information.

About Thomson Reuters

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.

CONTACTS

Daniel Meyer
GenoSpace, LLC
pr@genospace.com
(617) 520-4182

Laura Gaze
Thomson Reuters
laura.gaze@thomsonreuters.com
(203) 535-6283

BRENTWOOD, Tenn. (December 3, 2013) – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it has opened two new state-of-the-art facilities dedicated exclusively to molecular and cytology testing. The new laboratories are adjacent to PathGroup’s current laboratory at 658 Grassmere Park in Nashville, Tenn.

For Full Release, please CLICK HERE

Brentwood, Tenn.- (September 13, 2013) – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it will begin offering Next-Generation Sequencing (NGS) and Cytogenomic Array (Array-Based Comparative Genomic Hybridization [aCGH]) for genetic profiling of cancer patients in late Q3 of this year. PathGroup’s SmartGenomics™ Profile will provide community-based oncologists with access to tests and data to make more precise, personalized therapeutic recommendations.

For Full Release, please CLICK HERE

Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists

PHILADELPHIA, (August 13, 2013) — GenoSpace, PathGroup and the IP & Science business of Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.

Click Here to read the full article.

Brentwood, Tenn (May 30, 2013) -Dr. Pranil K. Chandra, Director of Molecular Pathology Services and Interim Medical Director of Clinical Pathology at PathGroup, is featured in the latest addition of CAP Today discussing how he and his molecular pathology team work to maintain gown-level care across multiple cities and states.

Click Here to read the full article.

Brentwood, Tenn. (September 30, 2012) – PathGroup, a leading provider of anatomic, clinical and molecular pathology services, launched an updated website today, www.pathgroup.com.  The new site comes after PathGroup unveiled, earlier this year, a new brand identity to include a revised logo and tagline; illustrating a contemporary identity and vision as the company adapts in an ever-changing healthcare environment. The redesigned site further demonstrates PathGroup’s industry expertise, breadth of capabilities, and will serve as a resource for customers and patients.

“Launching a refreshed identity as we expand into new markets will enable us to effectively communicate the central focus of PathGroup – to exceed the expectations of our clients and their patients,” said Richard Halstead, Senior Vice President and Chief Marketing Officer for PathGroup.  “Although this is a new look for PathGroup, the core foundation of the organization remains focused on providing industry leading anatomic, clinical and molecular pathology services.”

As one of the largest, private providers of pathology services in the United States, PathGroup continues to expand its service offering through organic growth initiatives and strategic merger and acquisitions.  With over 45 years of experience providing the highest quality services, PathGroup has over 700 employees and more than 70 pathologists representing every sub-specialty. The company’s longevity can be attributed to consistently exceeding the expectations of clients and patients. Direct access to PathGroup’s team of dedicated pathologists is a central focus of the organization, leading to better client relations and ultimately better patient outcomes.  This new identity and user-friendly website are reflective of that open culture.

“This is an exciting time for PathGroup and the clients we provide service to,” said Ben Davis, MD, PathGroup’s Chairman, President and CEO.  “We will continue to provide high quality care and evolve our organization as the healthcare industry changes.  Our goal is to meet the needs of those we provide services for, with a physician centered approach that is keenly focused on driving better patient outcomes. Staying at the forefront of advances in laboratory medicine is a critical component.”

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services.   Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships.  PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results.  The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service.  For more information, visit www.pathgroup.com

Teaneck, NJ, (September 18, 2012) – NeTLIMS^™ NJ, LLC, a provider of advanced Laboratory Information Systems (LIS), announced today that PathGroup, a provider of comprehensive anatomic, clinical and molecular pathology services based in Nashville, Tennessee, has selected the company’s AutoLims® advanced laboratory information system.

PathGroup works with more than 70 hospitals and thousands of group practices across the United States. Founded in 1965, the company has over 700 employees and more than 70 pathologists representing every sub-specialty. PathGroup will be utilizing AutoLims for its core lab, microbiology and genetics, allowing the company to maximize its productivity, efficiency and profitability through technological superiority, accuracy, ease of use and careful attention to customer needs.

“We chose to implement an LIS that would allow us to continue to deliver high quality service our customers have come to expect while streamlining our workflow,” said Ben Davis, M.D., President, Chairman and CEO for PathGroup. “The AutoLims product suite is a comprehensive tool that provides support from requisition to results and is customizable to meet our specific needs.”

AutoLims is a powerful and intuitive, easy-to-install LIS that covers all aspects of a clinical lab’s operation while providing lightning-fast responsiveness. It is comprised of a broad suite of very scalable and flexible advanced software modules that share the same underlying infrastructure, which can be easily and effectively adapted to support the full spectrum of IT needs of both hospital and commercial laboratories.

“The advanced architecture and design of AutoLims include the flexibility and power the laboratory information systems of this era must have to address the ever-evolving requirements of today’s laboratory,” remarked Ephraim Brand, President and Chief Executive Officer of NeTLIMS. “These features and the openness of the system will allow PathGroup to continue to grow and provide the same high quality of service its customers have come to expect.”

About PathGroup

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com.

About NeTLIMS NJ, LLC

NeTLIMS develops, markets and supports the AutoLIMS product suite. Since 1996, AutoLIMS has been powering hundreds of medium to very large clinical laboratories in hospitals and commercial laboratories worldwide. NeTLIMS customers include Quest Diagnostics, leading large (over 1,000 beds) state-of-the-art hospitals, HMOs (including Clalit Health Services – the world’s second largest HMO) and hundreds of laboratory installations, both nationally and globally. Simply powerful – AutoLIMS is lightning fast and extremely intuitive. AutoLIMS supports the complete needs of all types of clinical laboratories, from an individual lab specialty to a network of laboratories with multiple expertise. A perfect combination of excellent client services, cutting edge technology, unparalleled customizability and extendibility allows AutoLIMS to provide state-of-the-art solutions for all disciplines inside the laboratory and for all stages of the testing process. For additional information, please see: http://www.netlims.com.